TIMI RISK SCORE for STEMI

Slides:

Advertisements

Similar presentations

ACUTE CORONARY SYNDROMES “ACS”

Advertisements

Post-conditioning the human heart to reduce infarct size

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.

Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

on behalf of the TOTAL Investigators

Improved Care for Acute Myocardial Infarction Linking Referral and Receiving Centres – How can We Communicate Better? Dr. James McMeekin AMI Faculty Cardiologist,

Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.

1 UFH is Superior to Placebo for Reducing Mortality and Reinfarction in MI Pts Effect / 1,000 Pts Rx’d Routine ASA 68,000 Pts 93% Lysis Rx Collins R, et.

GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.

Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,

GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.

1 Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction ExTRACT- TIMI 25 ACC 2006 Atlanta, GA Disclosure Statement: Dr. Antman received.

MERLIN TIMI 36 M ETABOLIC E FFICIENCY WITH R ANOLAZINE FOR L ESS I SCHEMIA IN N STE ACS.

Evolution of pharmaceutical antithrombotic therapy in CVD Dr Rob Butler Dept of Cardiology University Hospital of North Staffordshire Drug It!

Background Fibrinolytic Rx in STEMI is limited by inadequate reperfusion and/or reocclusion in ~25% of pts. An occluded infarct-related artery is associated.

F. Van de Werf, ACC 2013 STREAM STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION.

Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,

Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.

What’s new in Acute Coronary Syndrome 2005?

Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.

ESC Congress 2007 RIGTH BUNDLE BRANCH BLOCK AS RISK MARKER OF IN HOSPITAL MORTALITY IN ST- ELEVATION ACUTE MYOCARDIAL INFARCTION. A RENASICA - II SUBSTUDY.

Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.

Disclosure Statement of Financial Interest

LESSON 1 LESSON 1 Establishment of:

Chapter Page, 12-Lead ECG for Acute and Critical Care Providers © 2006 by Pearson Education, Inc. Upper Saddle River, NJ Left Bundle Branch Block and Acute.

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Algebra II.  To remember everything in 1 st Semetser!

Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.

Prehospital NSTEMI Patient Assessment and Treatment

Cardiology Division, Jeju National University Hospital, Jeju, KOREA

Risk Stratification of Chest Pain: Best Practices

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

Antiplatelet therapy for STEMI: The Case for Clopidogrel

Improving Outcomes in Cardiogenic Shock

High capacity filling system

ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A

Tenecteplase (TNK-t-PA)‏

1224 STEMI pts, no reperfusion, < 24 hours from onset

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Unstable Angina and Non–ST Elevation Myocardial Infarction

STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES

NCVD Acute Coronary Syndrome (ACS) Registry An Update Dato’ Dr Azhari Rosman Chairman of NCVD ACS Registry Sentral Accord Room, Hilton Kuala Lumpur 19th.

Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH

Moderate/intermediate risk

TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI

Фейлетоните на Алеко Константинов

Fung TT, et al. Circulation 2009;119:

TIA/Stroke (1) C.L.I.P.S. Why do we care?

Single-Factor Dimensional Analysis

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Circulation 2001;104: Circulation 2001;104:

China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

OHSU - BDMS Heart CoE ACS Program

European Heart Journal Advance Access

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association between pioglitazone use and all-cause mortality.

Independent predictors of all-cause mortality at 30 days.

16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.

Presentation transcript:

TIMI RISK SCORE for STEMI HISTORICAL POINTS RISK SCORE 30-DAY MORTALITY IN InTIME II(%)* Age   75 65-74 3 2 1 2 3 4 5 6 7 8 >8 0.8 1.6 2.2 4.4 7.3 12 16 23 27 36 DM or HTN or angina 1 EXAM SBP < 100 mmHg 3 HR >100 bpm 2 Killip II-IV 2 Weight < 67 kg (150 lb) 1 PRESENTATION Anterior STE or LBBB 1 Time to Rx > 4 hrs 1 *Entry criteria: CP > 30 min, ST , sx onset < 6hrs, fibrinolytic-eligible RISK SCORE = Total points (0 -14) For more info go to www.timi.org Morrow et al. Circulation 2000; 102:2031-7